Clinical trial
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2…
NCT00251433 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00251433 |
|---|---|
| Title | GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer |
| Official title | An Open-label, Multicenter, Phase I/II Dose Escalation Study of Oral GW572016 in Combination With Docetaxel (Taxotere) Plus Trastuzumab (Herceptin) in Subjects Previously Untreated for ErbB2-overexpressing Metastatic Breast Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | lapatinib, docetaxel, trastuzumab |
| Enrollment | 53 |
| Start date | Sep 26, 2005 |
| Primary completion | Jun 10, 2010 |
| Completion | Jun 22, 2022 |
| First posted | Nov 10, 2005 |
| Last update posted | Mar 31, 2023 |
| Countries | France, Ireland, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: